Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash
‘Assume We Will Remain Sole Kabi Owner’ Under Potential Investments
The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.
You may also be interested in...
Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.